Show Notes
In this episode I speak with Dr. Emma Hapke, a leading psychiatrist, psychotherapist, and psychedelic researcher who ran the MAPS Canada MDMA trials in Montreal.Dr. Hapke provides an expert, on-the-ground look at the clinical trials and therapeutic process using substances like MDMA for PTSD and high-dose Psilocybin therapy for patients struggling with depression and end-of-life distress (fear of death/unprocessed grief).What you will learn:The Clinical Process: Dr. Hapke walks us through the intensive patient screening process, the preparation sessions, the high-dose treatment day, and the critical role of post-session integration and a two-therapist model.The Psychedelic Experience: Discover why these medicines are non-specific "amplifiers of the psyche" that facilitate a depth-oriented psychotherapeutic process. She cautions against the media narrative of a "brain reset," emphasizing that the medicines act as "catalysts for this deep work," which remains challenging for the patient.History and Future: We explore the deep history of altered consciousness and plant medicine in indigenous cultures, the 20th-century rediscovery with Albert Hofmann and LSD, and how the War on Drugs caused a decades-long setback for research.This discussion cuts through the "hope and the hype" to provide a clear, scientifically grounded view of where psychedelic medicine is today and its promise for the future of mental healthcare.Dr. Hapke's profile - https://www.uhn.ca/MentalHealth/Research/Psychedelic-Psychotherapy-Research/Pages/who-we-are.aspxIn Vivo on X - https://x.com/InVivoPodOnXIn Vivo on Youtube: https://www.youtube.com/@InVivoPodcastIn Vivo on Apple Podcast - https://podcasts.apple.com/us/podcast/in-vivo/id1775578563In Vivo on Amazon Podcasts - https://music.amazon.ca/podcasts/1ac4dbec-df46-4d1f-b0a1-742e9656ef44/in-vivo
More from In Vivo
Philosopher and historian of science Dr. Justin Garson joins me to unpack The Madness Pill: One Doctor’s Quest to Understand Schizophrenia, the mid-century hunt for a pill that could temporarily induce schizophrenia so scientists could reverse-engineer a cure.
Dr. Jason Kelly, co-founder and CEO of Ginkgo Bioworks, joins me to unpack autonomous labs, what they are, why biology’s bench tooling barely moved in 20 years, and why the right analogy isn’t a subway or a car, but a Waymo. Is the biology singularity around the corner?
Cathy Tie (founder, Origin Genomics) and Prof. Jiang Xueqin (Predictive History) join me for a wide-open conversation on germline gene editing, the science, the ethics, and the geopolitics.
Jason Verbelli, founder of Galilean Variance and CEO/Lead Engineer at SEG Magnetics, argues that Einstein left a written test for his own theory: if the speed of light depends even a little on the motion of the source, relativity and Einstein’s theory of gravitation are false. In this interview we start from first principles and work up through John Searl, magnetic waveforms, free energy vs over-unity, the double-slit experiments, the Casimir effect, and what that would mean for energy, technology, and space travel.
In this episode of In Vivo, I sit down with Dr. Rasmus Rosenberg Larsen, Assistant Professor of Forensic Epistemology at the University of Toronto and author of Psychopathy Unmasked: The Rise and Fall of a Dangerous Diagnosis (MIT Press).